

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (currently amended) A method to isolate *d*-*threo*-methylphenidate in greater than 99 percent enantiomeric excess from a mixture of *d*-*threo*-methylphenidate and *l*-*threo*-methylphenidate, comprising the steps of:

providing a racemic mixture comprising *d*-*threo*-methylphenidate and *l*-*threo*-methylphenidate;

treating said racemic mixture with a first optically active acid to obtain a second mixture of *d*-*threo*-methylphenidate and *l*-*threo*-methylphenidate from said racemic mixture, wherein said second mixture comprises *d*-*threo*-methylphenidate having greater than a 90 percent enantiomeric excess, wherein said first optically active acid does not comprise *l*-fenchyloxyacetic acid;

providing a mixture comprising *d*-*threo*-methylphenidate and *l*-*threo*-methylphenidate;

supplying *l*-fenchyloxyacetic acid;

treating said second mixture with said *l*-fenchyloxyacetic acid;

collecting *d*-*threo*-methylphenidate having greater than a 99 percent enantiomeric excess.

2. (original) The method of claim 1, wherein said supplying step further comprises the steps of:

providing *l*-fenchyl alcohol;

providing chloroacetic acid;  
reacting said *l*-fenchyl alcohol with said chloroacetic acid to form said *l*-fenchyloxyacetic acid.

3. (currently amended) The method of claim 1, wherein said treating step includes the following steps:

reacting said second mixture with said *l*-fenchyloxyacetic acid;  
isolating the salt of (1R)-endo-(+)-fenchyloxyacetic acid and *d*-*threo*-methylphenidate;  
and

cracking said salt of (1R)-endo-(+)-fenchyloxyacetic acid and *d*-*threo*-methylphenidate.  
4. (original) The method of claim 3, wherein said cracking step includes the following steps:

providing a 10 percent solution of sodium bicarbonate in water;  
treating the salt of (1R)-endo-(+)-fenchyloxyacetic acid and *d*-*threo*-methylphenidate with said aqueous sodium bicarbonate solution and ethyl acetate to give a two phase mixture comprising a water fraction and an ethyl acetate fraction;

separating the ethyl acetate fraction from said water fraction; and  
treating said ethyl acetate fraction with hydrochloric acid.

5. (original) The method of claim 4, further comprising the steps of:  
obtaining *l*-*threo*-methylphenidate from said water fraction;  
hydrolyzing said *l*-*threo*-methylphenidate to 1-*ritalinic* acid;  
reacting said 1-*ritalinic* acid with a methanol solution saturated with hydrogen chloride to form *dl*-methylphenidate.

6. (currently amended) A method to isolate *d*-*threo*-methylphenidate in greater than 99 percent enantiomeric excess from a racemic mixture of *d*-*threo*-methylphenidate and *l*-*threo*-methylphenidate, comprising the steps of:

providing a racemic mixture comprising *d*-*threo*-methylphenidate and *l*-*threo*-methylphenidate;

treating said racemic mixture with dibenzoyl-L-tartrate to obtain obtaining a second mixture of *d*-*threo*-methylphenidate and *l*-*threo*-methylphenidate from said racemic mixture, wherein said second mixture comprises *d*-*threo*-methylphenidate having greater than a 90 percent enantiomeric excess;

supplying *l*-fenchyloxyacetic acid;

treating said second mixture with said *l*-fenchyloxyacetic acid;

collecting *d*-*threo*-methylphenidate having greater than a 99 percent enantiomeric excess.

7. Canceled.

8. (currently amended) The method of claim 6, wherein said obtaining step includes the steps of:

reacting said racemic mixture with ~~an optically active acid~~ dibenzoyl-L-tartrate in methanol to give insoluble solids and a methanolic solution;

separating said insoluble solids and said methanolic solution;

adding water to said methanolic solution;

filtering said water / methanol solution to collect said second mixture.

9. (original) The method of claim 8, wherein said treating step includes:

reacting said second mixture with said *l*-fenchyloxyacetic acid;  
isolating the salt of (1R)-endo-(+)-fenchyloxyacetic acid and *d*-*threo*-methylphenidate;  
and

cracking said salt of (1R)-endo-(+)-fenchyloxyacetic acid and *d*-*threo*-methylphenidate.

10. (original) The method of claim 9, wherein said cracking step includes the following steps:

providing a 10 percent solution of sodium bicarbonate in water;

treating the salt of (1R)-endo-(+)-fenchyloxyacetic acid and *d*-*threo*-methylphenidate with said aqueous sodium bicarbonate solution and ethyl acetate to give a two phase mixture comprising a water fraction and an ethyl acetate fraction;

separating the ethyl acetate fraction from said water fraction; and

treating said ethyl acetate fraction with hydrochloric acid.

11. (original) The method of claim 8, wherein said insoluble solids comprises the adduct of *l*-*threo*-methylphenidate and said optically active-acid, further comprising the steps of:

forming 1-ritalinic acid from said insoluble solids;

providing a saturated solution of hydrogen chloride in methanol;

esterifying said 1-ritalinic acid using said saturated solution to form said racemic mixture.

12. (original) A method to resolve stereoisomers of an optically active compound comprising an amine moiety, comprising the steps of:

providing a mixture comprising two stereoisomers of a compound comprising a amine

moiety;

supplying *l*-fenchyloxyacetic acid;

treating said mixture with said *l*-fenchyloxyacetic acid;

collecting one of said two or more stereoisomers having greater than a 99 percent enantiomeric excess.

LAW OFFICE OF  
DALE F. REGELMAN, P.C.  
4231 S. Fremont Street  
Tucson, Arizona 85714

TEL 520-741-7638  
FAX 520-746-9114